A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Launched by SICHUAN BAILI PHARMACEUTICAL CO., LTD. · Jul 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a combination of two treatments, SI-B003 and BL-B01D1, to see how well they work in patients with advanced or spreading forms of non-small cell lung cancer and nasopharyngeal carcinoma, which is a type of throat cancer. The goal is to find out if this combination is safe, effective, and what the best dose may be for patients. The trial is currently looking for participants aged between 18 and 75 who have a confirmed diagnosis of these types of cancers and have at least one measurable tumor.

Eligible participants will need to sign a consent form and provide some medical history, including past treatments and current health status. They can expect to receive the study treatment and will be monitored closely for any side effects or response to the therapy. It's important to note that individuals with certain health conditions, like severe heart problems or other active infections, may not be able to participate. This study aims to provide new options for patients battling these challenging cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign the informed consent form voluntarily and follow the protocol requirements;
• • 2. Gender is not limited;
• • 3. Age: ≥18 years old and ≤75 years old;
• • 4. Expected survival time ≥3 months;
• • 5. Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma;
• • 6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
• • 7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
• • 8. ECOG 0 or 1;
• • 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
• • 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
• • 11. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements;
• • 12. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN;
• • 13. Urinary protein ≤2+ or ≤1000mg/24h;
• • 14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
• Exclusion Criteria:
• • 1. For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent;
• • 2. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
• • 3. Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;
• • 4. Use of immunomodulatory drugs within 14 days before the first dose of study drug;
• • 5. History of severe heart disease;
• • 6. QT prolongation, complete left bundle branch block, III degree atrioventricular block;
• • 7. Systemic corticosteroids or immunosuppressive agents are required within 2 weeks before study dosing;
• • 8. Active autoimmune and inflammatory diseases;
• • 9. Other malignancies diagnosed within 5 years before the first dose;
• • 10. Hypertension poorly controlled by two antihypertensive drugs;
• • 11. Pulmonary disease was defined as grade ≥3 according to CTCAE v5.0; Patients with current or history of ILD;
• • 12. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
• • 13. Patients with a large amount of serous cavity effusion, or serous cavity effusion with symptoms, or within 4 weeks before signing informed consent;
• • 14. Patients with active central nervous system metastases;
• • 15. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipients of the test drug;
• • 16. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
• • 17. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;
• • 18. Active infection requiring systemic therapy;
• • 19. Had participated in another clinical trial within 4 weeks before the first dose;
• • 20. The investigator did not consider it appropriate to use other conditions for participation in the trial.